Quick Answer
Enliven Therapeutics, Inc. reported Total Assets of $476.17 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed an increase of +46.2% in Total Assets from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $110.32 million | Q2 2020: $111.32 million | Q3 2020: $100.18 million | Q1 2021: $81.69 million | Q2 2021: $72.47 million | Q3 2021: $107.03 million | Q1 2022: $81.60 million | Q2 2022: $64.67 million | Q3 2022: $59.10 million | Q1 2023: $302.87 million | Q2 2023: $288.50 million | Q3 2023: $274.04 million | Q1 2024: $342.78 million | Q2 2024: $327.04 million | Q3 2024: $305.43 million | Q1 2025: $302.57 million | Q2 2025: $503.89 million | Q3 2025: $490.88 million.
- Over the full 7 years of available data (2019 to 2025), Enliven Therapeutics, Inc.'s Total Assets has grown by 1,330.0%.
- Historical annual values: Fiscal year 2025: $476.17 million | Fiscal year 2024: $325.76 million | Fiscal year 2023: $271.87 million | Fiscal year 2022: $83.30 million | Fiscal year 2021: $93.65 million | Fiscal year 2020: $90.84 million | Fiscal year 2019: $33.30 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: